We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi (SNY) Stock Outperforms Industry YTD: What's Next?
Read MoreHide Full Article
Sanofi’s (SNY - Free Report) Specialty Care unit is on a strong footing, particularly with the outstanding growth trajectory of its blockbuster immunology drug Dupixent, which has become the key top-line driver for the company.
Dupixent is now annualizing at close to €9.0 billion in sales after around five years on the market. Dupixent is approved in the United States and EU for five type II inflammatory diseases, namely severe chronic rhinosinusitis with nasal polyposis, severe asthma, moderate-to-severe atopic dermatitis, eosinophilic esophagitis and prurigo nodularis. Dupixent enjoys strong demand trends across all approved indications and geographies.
The frequent label expansion approvals are driving the drug’s sales higher. With accelerating outside U.S. revenues, multiple approvals for new indications and the expected expansion in younger patient populations, its sales are likely to rise further.
Sanofi expects Dupixent to achieve more than €13 billion in peak sales and €10 billion in 2023.
Sanofimarkets Dupixent in partnership with Regeneron (REGN - Free Report) . While sales are recorded by Sanofi, Regeneron records its share of profits/losses in connection with global sales of Dupixent.
Sanofi’s stock has risen 11.1% so far this year compared with the industry’s rise of 2.6%.
Image Source: Zacks Investment Research
The company has also launched several new drugs in the past couple of years and is expanding its pipeline through M&A deals. Key recent approvals/launches include Altuviiio (efanesoctocog alfa), Sanofi’s novel recombinant factor VIII therapy, which was approved for hemophilia A in the United States in February 2023 while Sanofi and partner AstraZeneca’s (AZN - Free Report) Beyfortus antibody for respiratory syncytial virus or RSV protection in all infants was approved in the United States in July 2023 and in the EU in November 2022.
Sanofi believes that its three new products launched/added in 2023, Altuviiio, AstraZeneca partnered Beyfortus and Tzield (added from the April 2023 acquisition Provention Bio) together can add up to at least €5 billion in peak sales. These drugs are expected to make up for the potential impact of generic competition on Aubagio. Aubagio generics were launched in the United States in March 2023 while in Europe, generics are expected to be launched in the fourth quarter.
Sanofi also possesses one of the world’s leading vaccine operations, with annual sales of more than €5 billion in the past five years. The company’s portfolio includes pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines and travel and endemic vaccines. Sanofi also has a strong position in both seasonal and pre-pandemic influenza vaccine spaces. Sanofi expects annual net sales to be more than €10 billion from its Vaccines unit by 2030, backed by its innovation efforts. It expects to deliver mid-to-high single-digit sales growth in its Vaccines unit.
Sanofi faces its share of headwinds like weak performance of diabetes drugs and recent negative pipeline development. Nonetheless, continued strong sales of Dupixent, contributions from new product launches, pipeline progress and regulatory updates should keep the stock afloat.
In the past 60 days, the consensus estimate for Alpine Immune Sciences’ 2023 loss has narrowed from $1.43 per share to $1.18 per share, while the same for 2024 has narrowed from $1.73 per share to $1.47 per share. Year to date, shares of Alpine Immune Sciences have rallied 59.2%.
ALPN’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average negative earnings surprise of 79.65%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Sanofi (SNY) Stock Outperforms Industry YTD: What's Next?
Sanofi’s (SNY - Free Report) Specialty Care unit is on a strong footing, particularly with the outstanding growth trajectory of its blockbuster immunology drug Dupixent, which has become the key top-line driver for the company.
Dupixent is now annualizing at close to €9.0 billion in sales after around five years on the market. Dupixent is approved in the United States and EU for five type II inflammatory diseases, namely severe chronic rhinosinusitis with nasal polyposis, severe asthma, moderate-to-severe atopic dermatitis, eosinophilic esophagitis and prurigo nodularis. Dupixent enjoys strong demand trends across all approved indications and geographies.
The frequent label expansion approvals are driving the drug’s sales higher. With accelerating outside U.S. revenues, multiple approvals for new indications and the expected expansion in younger patient populations, its sales are likely to rise further.
Sanofi expects Dupixent to achieve more than €13 billion in peak sales and €10 billion in 2023.
Sanofimarkets Dupixent in partnership with Regeneron (REGN - Free Report) . While sales are recorded by Sanofi, Regeneron records its share of profits/losses in connection with global sales of Dupixent.
Sanofi’s stock has risen 11.1% so far this year compared with the industry’s rise of 2.6%.
Image Source: Zacks Investment Research
The company has also launched several new drugs in the past couple of years and is expanding its pipeline through M&A deals. Key recent approvals/launches include Altuviiio (efanesoctocog alfa), Sanofi’s novel recombinant factor VIII therapy, which was approved for hemophilia A in the United States in February 2023 while Sanofi and partner AstraZeneca’s (AZN - Free Report) Beyfortus antibody for respiratory syncytial virus or RSV protection in all infants was approved in the United States in July 2023 and in the EU in November 2022.
Sanofi believes that its three new products launched/added in 2023, Altuviiio, AstraZeneca partnered Beyfortus and Tzield (added from the April 2023 acquisition Provention Bio) together can add up to at least €5 billion in peak sales. These drugs are expected to make up for the potential impact of generic competition on Aubagio. Aubagio generics were launched in the United States in March 2023 while in Europe, generics are expected to be launched in the fourth quarter.
Sanofi also possesses one of the world’s leading vaccine operations, with annual sales of more than €5 billion in the past five years. The company’s portfolio includes pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines and travel and endemic vaccines. Sanofi also has a strong position in both seasonal and pre-pandemic influenza vaccine spaces. Sanofi expects annual net sales to be more than €10 billion from its Vaccines unit by 2030, backed by its innovation efforts. It expects to deliver mid-to-high single-digit sales growth in its Vaccines unit.
Sanofi faces its share of headwinds like weak performance of diabetes drugs and recent negative pipeline development. Nonetheless, continued strong sales of Dupixent, contributions from new product launches, pipeline progress and regulatory updates should keep the stock afloat.
Zacks Rank & Stock to Consider
Sanofi currently has a Zacks Rank #3 (Hold).
Sanofi Price and Consensus
Sanofi price-consensus-chart | Sanofi Quote
A better-ranked drug/biotech company worth considering is Alpine Immune Sciences (ALPN - Free Report) , which has a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, the consensus estimate for Alpine Immune Sciences’ 2023 loss has narrowed from $1.43 per share to $1.18 per share, while the same for 2024 has narrowed from $1.73 per share to $1.47 per share. Year to date, shares of Alpine Immune Sciences have rallied 59.2%.
ALPN’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average negative earnings surprise of 79.65%.